A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer

Annals of Oncology

Volumn 25, Issue 11, 2014, Pages 2156-2162

  Novello, S ^a   Besse, B ^b   Felip, E ^c   Barlesi, F ^d   Mazieres, J ^e   Zalcman, G ^f   von Pawel, J ^g   Reck, M ^h   Cappuzzo, F ⁱ   Ferry, D ^j   Carcereny, E ^k   Santoro, A ^l   Garcia Ribas, I ^m   Scagliotti, G ^a   Soria, J C ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d AIX MARSEILLE UNIVERSITY   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f CHU CÔTE DE NACRE   (France)

^g ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^h Member of the German Center for Lung Research   (Germany)

ⁱ ISTITUTO TOSCANO TUMORI   (Italy)

^j NEW CROSS HOSPITAL   (United Kingdom)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^m Sanofi Aventis   (Spain)

more..

Author keywords

Advanced disease; First line therapy; Iniparib; Non small cell lung cancer

Indexed keywords

CISPLATIN; GEMCITABINE; INIPARIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; DEOXYCYTIDINE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEARING IMPAIRMENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TINNITUS; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 84934284396     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu384     Document Type: Article

References (12)

1. Liu X, Shi Y, Maag DX et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012; 18(2): 510-523.
2. Licht S, Cao H, Li Z et al. Mechanism of action of iniparib: stimulation of reactive oxygen species (ROS) production in an iniparib-sensitive breast cancer cell line. Mol Cancer Ther 2011; 10(Suppl 1): Abstract 226.
3. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364(3): 205-214.
4. O'Shaughnessy J, Schwartzberg L, Danso M et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29(Suppl): Abstract 1007.
5. Le Chevalier T, Scagliotti G, Natale R et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005; 47(1): 69-80.
6. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26(21): 3543-3551.
7. Di Maio M, Gallo C, De Maio E et al. Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer 2010; 67(2): 127-135.
8. Paz-Ares L, Douillard J-Y, Koralewski P et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2006; 24(9): 1428-1434.
9. Paz-Ares LG, Biesma B, Heigener D et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012; 30(25): 3084-3092.
10. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAiL. J Clin Oncol 2009; 27(8): 1227-1234.
11. Manegold C, van Zandwijk N, Szczesna A et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2012; 23(1): 72-77.
12. Spigel DR, Kim ES, Lynch TS et al. Randomized phase III trial of gemcitabine (G)/carboplatin (C) with or without iniparib (I) in patients ( pts) with previously untreated stage IV squamous lung cancer. J Thor Oncol 2013; 8(Suppl 2): Abstract #O15.06.